Market closed
Denali Therapeutics/$DNLI
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Denali Therapeutics
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
Ticker
$DNLI
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
390
Website
DNLI Metrics
BasicAdvanced
$3B
-
-$2.73
1.39
-
Price and volume
Market cap
$3B
Beta
1.39
52-week high
$31.56
52-week low
$14.56
Average daily volume
956K
Financial strength
Current ratio
9.976
Quick ratio
9.621
Long term debt to equity
3.374
Total debt to equity
3.983
Interest coverage (TTM)
-5,125.04%
Management effectiveness
Return on assets (TTM)
-23.81%
Return on equity (TTM)
-35.09%
Valuation
Price to book
2.26
Price to tangible book (TTM)
2.26
Price to free cash flow (TTM)
-8.636
Growth
Revenue change (TTM)
-100.00%
Earnings per share change (TTM)
198.65%
3-year earnings per share growth (CAGR)
126.24%
What the Analysts think about DNLI
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Denali Therapeutics stock.
DNLI Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
DNLI Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
DNLI News
AllArticlesVideos
Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa
GlobeNewsWire·2 weeks ago
Why Is Denali Therapeutics Stock Trading Higher On Wednesday?
Benzinga·1 month ago
Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains
Seeking Alpha·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Denali Therapeutics stock?
Denali Therapeutics (DNLI) has a market cap of $3B as of February 23, 2025.
What is the P/E ratio for Denali Therapeutics stock?
The price to earnings (P/E) ratio for Denali Therapeutics (DNLI) stock is 0 as of February 23, 2025.
Does Denali Therapeutics stock pay dividends?
No, Denali Therapeutics (DNLI) stock does not pay dividends to its shareholders as of February 23, 2025.
When is the next Denali Therapeutics dividend payment date?
Denali Therapeutics (DNLI) stock does not pay dividends to its shareholders.
What is the beta indicator for Denali Therapeutics?
Denali Therapeutics (DNLI) has a beta rating of 1.39. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.